NCT04288687View on ClinicalTrials.gov

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer with DNA Repair Defects

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

February 20, 2024

Study Completion Date

February 20, 2024

Conditions
Prostate Adenocarcinoma
Interventions
DRUG

Niraparib Pill

Niraparib 200 mg by mouth daily (2 x 100 mg pills)

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT04288687 - A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer with DNA Repair Defects | Biotech Hunter | Biotech Hunter